Bay BioSciences

Executive Summary

Bay BioSciences is a US-based biomedical company that provides ethically sourced human biospecimens, including tissue samples, biofluids, and associated clinical data, primarily for oncology and rare disease research. Founded in 2018 and headquartered in San Francisco, the company operates a global biobank network serving pharmaceutical firms, biotech companies, and CROs. Its mission is to accelerate drug discovery by offering high-quality, well-annotated samples that are critical for translational research. The company's differentiated focus on rare diseases and stringent ethical sourcing positions it well in a market where demand for high-quality biospecimens is growing, driven by precision medicine and biomarker development. However, as a private entity with limited public financial disclosures, visibility into its performance and growth trajectory is constrained. The company faces competition from established biobanks and may need to scale its network to capture broader market share. Overall, Bay BioSciences operates in a niche but essential segment of the life sciences ecosystem.

Upcoming Catalysts (preview)

• Q4 2026Expansion of rare disease biobank through strategic partnerships70% success
• Q2 2027Launch of AI-powered sample matching platform50% success